--- title: "Cue Biopharma, Inc. (CUE.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/CUE.US.md" symbol: "CUE.US" name: "Cue Biopharma, Inc." industry: "Biotechnology" datetime: "2026-05-19T16:10:28.367Z" locales: - [en](https://longbridge.com/en/quote/CUE.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/CUE.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/CUE.US.md) --- # Cue Biopharma, Inc. (CUE.US) ## Company Overview Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.cuebiopharma.com](https://www.cuebiopharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:12.000Z **Overall: B (0.28)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 54 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 309.60% | | | Net Profit YoY | 51.89% | | | P/B Ratio | 3.22 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 69599575.42 | | | Revenue | 32731000.00 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -138.52% | E | | Profit Margin | -59.65% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 309.60% | A | | Net Profit YoY | 51.89% | B | | Total Assets YoY | 38.75% | A | | Net Assets YoY | 228.39% | A | | Cash Flow Margin | 125.27% | B | | OCF YoY | 309.60% | A | | Turnover | 1.23 | A | | Gearing Ratio | 30.02% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Cue Biopharma, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "309.60%", "rating": "" }, { "name": "Net Profit YoY", "value": "51.89%", "rating": "" }, { "name": "P/B Ratio", "value": "3.22", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "69599575.42", "rating": "" }, { "name": "Revenue", "value": "32731000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "-138.52%", "rating": "E" }, { "name": "Profit Margin", "value": "-59.65%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "309.60%", "rating": "A" }, { "name": "Net Profit YoY", "value": "51.89%", "rating": "B" }, { "name": "Total Assets YoY", "value": "38.75%", "rating": "A" }, { "name": "Net Assets YoY", "value": "228.39%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "125.27%", "rating": "B" }, { "name": "OCF YoY", "value": "309.60%", "rating": "A" }, { "name": "Turnover", "value": "1.23", "rating": "A" }, { "name": "Gearing Ratio", "value": "30.02%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -3.57 | 325/386 | - | - | - | | PB | 3.22 | 265/386 | 7.28 | 3.14 | 2.07 | | PS (TTM) | 2.13 | 54/386 | 7.22 | 6.04 | 3.61 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-15T04:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 20.73 | | Highest Target | 115.00 | | Lowest Target | 115.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CUE.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CUE.US/norm.md) - [Related News](https://longbridge.com/en/quote/CUE.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CUE.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**